Precautions when using nirogacestat

Nirogacestat (nirogacestat) is a new anti-cancer drug that has shown certain efficacy in clinical studies, but it also comes with a series of warnings and precautions. A variety of adverse effects, including diarrhea, ovarian toxicity, hepatotoxicity, non-melanoma skin cancer, electrolyte abnormalities, and embryo-fetal toxicity, have been observed in patients treated with nilogalstat. Therefore, these potential risks must be fully understood and monitored before using this drug.

First, diarrhea is a common side effect in patients receiving nirogalastat. To effectively manage this condition, it is recommended that the patient's intestinal health be monitored regularly and antidiarrheal medications be given if necessary. According to clinical guidance, if the diarrhea is severe enough to affect the patient's quality of life, the use of nirogastat should be suspended and treatment should be restarted at a dose of 100 mg twice daily after symptoms have reduced to grade ≤ 1 or returned to baseline.

Second, female patients may be at risk for ovarian toxicity during treatment with nirogalastat. This toxicity may affect the patient's reproductive function and fertility, the extent of which depends on several factors, including the duration of treatment and the patient's gonadal status. The long-term effects of nirogastat on fertility are unknown, so doctors should inform patients about the potential risk of ovarian toxicity before starting treatment. At the same time, the patient's menstrual cycle and estrogen deficiency symptoms (such as hot flashes, night sweats, etc.) need to be continuously monitored.

In addition, hepatotoxicity is also an important concern during nirogastat treatment, and there is an increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST). Therefore, regular liver function testing is crucial. If ALT or AST levels are found to be more than three times the upper limit of normal, the dose should be adjusted promptly or nirogalastat should be discontinued until liver function indicators return to normal, and treatment should be resumed at a dose of 100 mg after recovery.

Non-melanoma skin cancers (such as squamous cell carcinoma and basal cell carcinoma) are also among the risks that patients receiving nirogalastat may face. Therefore, routine dermatological evaluation is recommended before patients start receiving nirogalastat and during treatment to identify and treat any skin lesions promptly.

Electrolyte abnormalities are also of concern during nirogalastat treatment, particularly phosphate and potassium levels. Therefore, it is recommended that patients' electrolyte levels be monitored regularly and supplemented when necessary. At the same time, if the electrolyte abnormality is severe, consideration should be given to suspending the use of nirogastat and restarting treatment at a low dose after the indicators recover.

Finally, embryo-fetal toxicity is also an important warning when using nirogalastat in pregnant women. Animal studies have shown that this drug may cause harm to the fetus during pregnancy. Oral administration of nirogastat to pregnant rats can cause embryo-fetal toxicity, especially during organogenesis, and female patients must be informed of the risks before initiating treatment. Women and men of reproductive potential should use effective contraception during treatment and for at least one week after the last dose to reduce potential risks to the fetus.

Reference materials:https://www.drugs.com/mtm/nirogacestat.html